Physician profile
Barbara Wezenter
NPI 1437374543
$3,505.29
in general payments reported to CMS, 2019-2025
30 companies · $537 in 2025
The $537 reported for 2025 was more than what a typical Endocrinology, Diabetes & Metabolism provider received nationally (typical 2025 total: $506).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $617 · 2020: $624 · 2021: $245 · 2022: $527 · 2023: $483 · 2024: $472 · 2025: $537.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,492.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,492.49 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $424.39 | 2019-2025 | Freestyle Libre 3 |
| Xeris Pharmaceuticals, INC. | $295.67 | 2020-2025 | Gvoke Hypopen, Recorlev |
| Amneal Pharmaceuticals LLC | $280.00 | 2021-2025 | Unithroid |
| Amgen INC. | $271.97 | 2020-2025 | Evenity, Prolia, Repatha |
| Lilly USA, LLC | $266.14 | 2019-2025 | Mounjaro, Zepbound, Jardiance |
| Radius Health, INC. | $244.74 | 2019-2023 | Tymlos |
| Dexcom, INC. | $233.26 | 2021-2023 | Dexcom G6 Transmitter |
| Novo Nordisk INC | $166.11 | 2019-2022 | |
| Sanofi-Aventis U.S. LLC | $153.21 | 2019-2021 | |
| Pfizer INC. | $147.32 | 2020-2023 | |
| Astrazeneca Pharmaceuticals Lp | $135.46 | 2019-2024 | |
| Vifor Pharma, INC. | $123.35 | 2019-2020 | |
| Corcept Therapeutics | $122.29 | 2021-2023 | Korlym |
| Mannkind Corporation | $92.68 | 2019-2022 | |
| Insulet Corporation | $89.42 | 2019 |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Chiesi USA, INC. | $67.46 | 2025 | Mycapssa |
| Janssen Pharmaceuticals, INC | $57.20 | 2023 | Xarelto |
| Zealand Pharma US, INC. | $51.44 | 2020-2021 | |
| Recordati_rare_diseases_inc. | $46.25 | 2025 | Isturisa |
| Ferring Pharmaceuticals INC. | $37.50 | 2019 | |
| Alexion Pharmaceuticals, INC. | $30.81 | 2022-2024 | Strensiq |
| Esperion Therapeutics, INC. | $29.39 | 2024 | Nexletol |
| Janssen Scientific Affairs, LLC | $22.13 | 2022 | |
| Ipsen Biopharmaceuticals, INC | $21.88 | 2019 | |
| Medtronic, INC. | $19.44 | 2024 | Minimed 780g |
| Ascendis Pharma Endocrinology INC | $17.79 | 2023 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $17.76 | 2024 | Cycloset |
| Tandem Diabetes Care, INC. | $14.83 | 2022 | |
| Merck Sharp & Dohme LLC | $14.29 | 2020 | |
| Arbor Pharmaceuticals, INC. | $11.11 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Barbara Wezenter listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.